Table 1.
Patient Characteristics
| All Patients (N=124) |
|
|---|---|
| Age at Diagnosis, years | |
| Mean (SD) | 67.8 (10.6) |
| Median (range) | 69.79 (30.68 – 88.18) |
| Months from Diagnosis to First Visit | |
| Mean (SD) | 21.1 (32.8) |
| Median (range) | 5.88 (0 – 206.7) |
| Sex | |
| Male | 83 (66.9%) |
| Female | 41 (33.1%) |
| Race | |
| White | 92 (74.2%) |
| Non-White | 11 (8.9%) |
| Unknown | 21 (16.9%) |
| Marital Status | |
| Not Married | 20 (16.1%) |
| Married | 84 (67.7%) |
| Unknown | 20 (16.1%) |
| Health Insurance | |
| Medicare | 87 (70.2%) |
| Medicaid | 3 (2.4%) |
| Private payer | 30 (24.2%) |
| Other | 4 (3.2%) |
| MDS Subtype | |
| Refractory anemia (RA) | 9 (7.3%) |
| Refractory cytopenia with unilineage dysplasia (RCUD) | 2 (1.6%) |
| Refractory cytopenia with multilineage dysplasia (RCMD) | 42 (34.1%) |
| Refractory anemia with ring sideroblasts (RARS) | 16 (13.0%) |
| Refractory anemia with excess blasts (RAEB) | 43 (35.0%) |
| Myelodysplastic syndrome associated with del(5q) | 7 (5.7%) |
| Myelodysplastic syndrome, unclassifiable | 3 (2.4%) |
| Unknown | 1 (0.8%) |
| Risk Stratificationa | |
| Low | 60 (48.4%) |
| Intermediate | 26 (21.0%) |
| High | 38 (30.6%) |
| Cancer History | |
| No | 88 (71.0%) |
| Yes | 36 (29.0%) |
| Died During Study Period | |
| Yes | 25 (20.2%) |
| No | 99 (79.8%) |
| Progressed to AML | |
| No | 119 (96.0%) |
| Yes | 5 (4.0%) |
a
Risk stratification is based on the International Prognostic Scoring System (IPSS) or IPSS-R where available. For patients with unknown IPSS/R (N=45) the World Health Organization Prognostic Scoring System (WPSS) was used based on information obtained from the diagnosis visit.